Tag:
Development deals
Latest Headlines
Latest Headlines
UPDATED: MiRagen lands $352M microRNA development pact with Servier
Boulder, CO-based miRagen has racked up its first big collaboration, inking a development pact with France's Servier for two of its top preclinical programs as well as a third, as yet unidentified,
Enanta lands $43M NIAID development contract
Watertown, MA-based Enanta Pharmaceuticals reports that it has won a 5-year development contract with the National Institute of Allergy and Infectious Diseases (NIAID) which will provide up to $42.7
UPDATED: Agios wins $20M haul as Celgene extends cancer development pact
It didn't take long for Cambridge, MA-based Agios Pharmaceuticals to win a rep in the drug development field. Launched in 2008 with $33 million from a trio of venture groups with a well-known taste
Ambrx banks $24M BMS check as it adds two new development deals
Bristol-Myers Squibb ($BMY) is handing Ambrx an upfront payment of $24 million to buy itself a ticket to ride on the La Jolla, CA-based biotech's discovery platform. Adding to a string of
KAI banks $13M in development deal with Japan's Ono
South San Francisco-based KAI Pharmaceuticals has inked a Japanese development and marketing deal for its lead therapy, nabbing a $13 million upfront payment from Ono Pharmaceutical. Now nearing the
Fierce 15 f-star lands $708M antibody pact with Merck Serono
A day after being spotlighted as one of this year's Fierce 15 biotechs, f-star announced that it has inked a $708 million development deal with Merck Serono. In the deal, the Vienna-based biotech
Merck, Serum Institute sign pneumococcal vaccine deal
Merck ($MRK) and the Serum Institute of India are joining forces to bring a pneumococcal conjugate vaccine to emerging and developing markets. The deal includes a product advisory committee that will
Celgene tackles anemia in $242M development pact with Acceleron
Celgene and Acceleron are taking their drug development relationship one big step forward in a new direction. Celgene announced this morning that is partnering up with Acceleron on a new, early-stage
GSK, Arecor form vaccine stabilization pact
GlaxoSmithKline and Arecor have entered a collaboration to advance GSK's vaccines using Arecor's stabilization technology. Exact financial detail weren't disclosed, but the company's release stated
Booming AVEO inks $555M antibody deal with J&J;
With its lead cancer drug forging ahead in Phase III and a major development deal with Astellas helping pay for a burgeoning staff, Cambridge, MA-based AVEO announced a new development pact with
